AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Celltrion's asthma treatment Omlyclo, a biosimilar of Novartis's Xolair, has received Canadian approval for chronic urticaria, rhinosinusitis, and allergic asthma ...

Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...

A new study published in the Ear, Nose and Throat Journal found that the severity of chronic rhinosinusitis with nasal ...

"Medical Journeys" chart a path each step of the way for physicians and patients and provide continual resources and support, ...

US FDA accepts GSK’s submission for the use of Nucala to treat patients with chronic obstructive pulmonary disease: London, UK Wednesday, December 11, 2024, 10:00 Hrs [IST] GSK ...

The FDA has accepted for review the BLA for mepolizumab as an add-on maintenance treatment for eosinophilic COPD.

Do you find yourself sneezing, itching or battling watery eyes as the seasons change? If so, you may have a pollen ...

The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala ...

Group 2 Innate lymphoid cells (ILC2) are a source of type 2 cytokines, such as interleukin-5 (IL-5). Here Troch, Jakob et al. show a non-redundant role of ILC2-derived IL-5 required for the ...

Whether you want passive income or not, dividend-paying stocks tend to outperform their non-dividend-paying cousins.